The use of anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) monoclonal antibodies (mAbs) or mAbs targeting the programmed death receptor and its ligand (PD-1 and PD-L1, respectively), has generated tremendous interest in the ability to assess and treat cancer patients by harnessing the immune system, revealing the broad-spectrum and tumor agnostic strategy of such therapies [7,8,9,10,11,12,13,14]. This evidence concerns the gene CD274 and cancer.